Bedrijfsoverzicht
PolyPid Ltd. is a biopharmaceutical entity dedicated to the development of targeted, locally administered, and prolonged-release therapeutics that utilize its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address significant unmet medical needs. The company operates within the broader Healthcare sector and specifically functions in the Biotechnology industry, a classification that indicates a focus on early-stage research and development rather than mature manufacturing operations. Its current market capitalization stands at $82.25M, while its annual revenue is not disclosed in the available data, and it employs a workforce of 69 individuals. The market cap figure of $82.25M, combined with the absence of reported revenue, suggests that the company is in a capital-intensive phase where valuation is driven primarily by intellectual property potential and clinical trial progress rather than current profit generation or sales volume.
Financiële gezondheid
The company reports a net income of $-34,169,000 for the trailing twelve months, while its EBITDA is recorded at $-31,509,000 and revenue is listed as N/A; the substantial gap between the reported net income loss and the EBITDA loss reveals a significant cost structure burden driven by non-operating expenses such as interest or taxes that are not captured in the operational EBITDA metric. Free cash flow stands at $-15,795,625, which indicates that the company is currently burning cash to fund its development pipeline rather than generating liquidity for operations or debt servicing. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, a figure that typically signifies a company that has not yet achieved commercial sales or is operating at a scale where revenue does not cover the direct costs of goods sold and overhead expenses. In terms of solvency, the company holds $12.93M in cash against $2.80M in debt, resulting in a debt-to-equity ratio of 25.48, which suggests a balance sheet that relies heavily on equity financing rather than leverage, though the negative earnings impact the equity base significantly. Short-term liquidity is supported by a current ratio of 1.97, indicating that the company possesses nearly double the current assets required to meet its current liabilities. Return on Equity is -366.3% and Return on Assets is -86.7%, metrics that reveal management is currently deploying capital to generate losses rather than positive returns, reflecting the high-risk nature of biotechnology development before product approval.
Waarderingsbeoordeling
The valuation multiples for PolyPid are constrained by its lack of profitability, with a trailing P/E ratio listed as N/A and a forward P/E of -4.66, implying that the market does not expect immediate earnings recovery in the near term. The price-to-book ratio is 7.15, which indicates that the market is pricing the company at a significant premium over its book value, a common phenomenon in biotech firms where investor sentiment focuses on future clinical outcomes rather than current asset values. Alternative valuation metrics such as the price-to-sales ratio, which is N/A, and the EV/EBITDA of -2.29, suggest that traditional valuation frameworks are inapplicable, forcing reliance on clinical milestones for value assessment. The stock has traded between a 52-week low of $2.44 and a 52-week high of $5.12, placing the current valuation context within a wide historical range where the upper limit reflects peak investor optimism regarding the PLEX technology. The beta value is 1.46, meaning the stock price is expected to exhibit 46% higher volatility than the broader market, reflecting the heightened sensitivity of biotechnology assets to sector-specific news and regulatory developments.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, which prevents a direct comparison of growth rates but underscores that the company is not yet in a mature commercialization stage where revenue scaling is the primary performance indicator. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available cash flows are being reinvested into research, development, and clinical trials rather than being distributed to shareholders. The absence of dividend income aligns with the company's lifecycle stage, where capital retention is essential to sustain operations and advance the lead product candidate D-PLEX100 through pivotal Phase 3 trials. The overall growth and income profile is characterized by a reliance on external capital markets to fund operations due to the lack of positive cash flow and the absence of income generation mechanisms like dividends or substantial revenue growth.